Tropical & Infectious Disease ELISA
From Dengue NS1 and IgG/IgM serology across all four serotypes to Zika envelope protein, Chikungunya, Yellow Fever, Japanese Encephalitis, Rabies glycoprotein, Hepatitis B/C, RSV, Influenza, CRM197 vaccine manufacturing QC, and dsRNA innate immunity ELISA — Krishgen's infectious disease platform covers the pathogens that matter most to researchers in Asia, Africa, and Latin America in 2026.
Four Integrated Infectious Disease Research Areas
Krishgen's infectious disease ELISA portfolio is built around the pathogens driving the greatest research investment globally in 2026. The range spans arboviral serology, vaccine manufacturing QC, respiratory and hepatic viruses, and archived SARS-CoV-2 research assays — all KRIBIOLISA™ or GENLISA™ branded, ISO 13485-manufactured in Mumbai and California.
Infectious Disease Assay Targets
Filter by pathogen class to find the right ELISA. All kits are sandwich ELISA, HRP/TMB colorimetric, 96-well break-apart, ISO 13485-manufactured. Validated against Krishgen's seven-point "Gold Ring" QC protocol.
Dengue affects 400 million people annually across 100+ countries. ELISA-based serology distinguishes primary from secondary infection, measures vaccine-induced IgG seroconversion, and detects NS1 antigen during the pre-antibody viraemic window. All four DENV serotypes are covered.
View Dengue ELISA →Zika (ZIKV) causes congenital microcephaly in neonates of infected mothers. Krishgen offers two orthogonal antigen assays — NS1 protein (KBVH650, 50 pg/ml) for acute detection and envelope protein (KBVH700, 180 pg/ml) for vaccine antigen characterisation — plus IgG/IgM serology.
View Zika NS1 ELISA →CHIKV is a re-emerging alphavirus causing debilitating polyarthralgia, now endemic in over 100 countries. IgM ELISA identifies acute infection; IgG ELISA monitors vaccine-induced immunity. Increasingly relevant as the first licensed chikungunya vaccines enter post-marketing surveillance.
View Chikungunya ELISA →Yellow Fever Virus is endemic across tropical Africa and South America. Live-attenuated 17D vaccine is highly effective but under-utilised. IgG ELISA (KBVH605, 30 ng/ml) measures post-vaccination protective antibody; IgM ELISA (KBVH606) identifies breakthrough acute infection in vaccinated populations.
View Yellow Fever ELISA →JEV is the leading cause of viral encephalitis in Asia, with an estimated 68,000 cases annually. Inactivated Vero cell-derived and live-attenuated vaccines require IgG titration ELISA and plaque reduction neutralisation support for immunogenicity endpoints. IgM ELISA confirms active infection in non-immune populations.
View JEV ELISA →Krishgen's five-assay rabies panel is among the most comprehensive available in ELISA format: glycoprotein antigen (KBVH177), nucleoprotein antigen (KBVH180), and three IgG antibody assays targeting subtypes 1, 2, 3 across both structural proteins. Covers pre-exposure prophylaxis monitoring, post-exposure serology, and vaccine potency assessment.
View Rabies panel →HBV remains endemic across South and Southeast Asia with over 296 million chronic carriers globally. Anti-HBs titre ≥10 mIU/ml is the standard correlate of vaccine-induced protection. Krishgen's HBV panel covers all four major antigen and antibody targets used in vaccination monitoring and antiviral treatment assessment.
View HBV ELISA →HCV infects ~58 million people globally with no licensed vaccine. Anti-HCV antibody ELISA are used for seroprevalence studies and novel vaccine candidate evaluation in animal models. Antigen assays support viral load surrogate measurement and mechanism-of-action studies.
View HCV ELISA →Annual influenza vaccination requires strain-specific and cross-reactive immunogenicity ELISA. Antibody assays for Influenza A (including H1N1, H3N2) and Influenza B measure post-vaccination seroconversion in serum and plasma — supporting seasonal and pandemic influenza vaccine evaluation programmes.
View Influenza ELISA →RSV is the leading cause of lower respiratory tract infection in infants and immunocompromised adults. With prefusion F protein-based RSV vaccines now approved and entering widespread use, antigen and antibody ELISA support post-market immunogenicity monitoring and mechanistic research into protection correlates.
View RSV ELISA →Krishgen's 50+ SARS-CoV-2 assay panel covers spike (S1, S2, RBD, whole spike), nucleocapsid, envelope, and membrane protein — in human, mouse, rat, hamster, and rabbit. Six surrogate virus neutralisation tests (sVNT) cover major variant lineages. Maintained for ongoing COVID-related and long-COVID research.
View SARS-CoV-2 assays →Key Biomarkers & Antigens by Pathogen
Select a pathogen to explore the key antigens, antibody isotypes, and research applications covered by Krishgen's ELISA kits.
Dengue Virus — NS1 Antigen, IgG, IgM & Serotype Biology
Dengue is caused by four antigenically distinct serotypes (DENV-1 through DENV-4); secondary heterotypic infection carries increased risk of severe dengue through antibody-dependent enhancement (ADE). ELISA-based serology distinguishes primary from secondary dengue, determines seroprevalence, and measures vaccine-induced immunity in tetravalent vaccine programmes. The NS1 antigen is secreted during the viraemic phase (days 1–5 post-onset) before IgM antibody responses develop — making it the ideal early diagnostic target. IgM peaks at 7–10 days; IgG persists long-term and is the primary immunogenicity endpoint in dengue vaccine trials.
Zika Virus — NS1, Envelope Protein & Congenital Zika Serology
Zika virus (ZIKV), a flavivirus closely related to dengue, causes congenital Zika syndrome including microcephaly. Serological cross-reactivity with dengue and other flaviviruses complicates diagnosis. Krishgen's NS1 ELISA (KBVH650, 50 pg/ml) provides antigen-based detection; the envelope protein ELISA (KBVH700, 180 pg/ml) supports vaccine antigen characterisation for subunit and mRNA vaccine candidates. Both are validated against the SPH2015 reference strain — the strain used in most active vaccine development programmes. IgG and IgM serology support seroprevalence studies in endemic populations and maternal cohort monitoring for congenital Zika risk assessment.
Rabies Virus — Glycoprotein, Nucleoprotein & Post-Vaccination Serology
Rabies lyssavirus has a 100% case fatality rate once symptomatic. The WHO-recommended minimum protective titre post-vaccination is ≥0.5 IU/ml (by RFFIT). Krishgen's glycoprotein IgG ELISA (KBVH377) correlates with RFFIT neutralisation and is used for post-exposure prophylaxis (PEP) monitoring and pre-exposure prophylaxis (PrEP) titre verification in high-risk occupational cohorts (veterinarians, wildlife workers). The nucleoprotein IgG (KBVH277) detects cross-reactive antibody responses shared across lyssavirus genotypes, supporting research into cross-clade protection. Antigen assays (KBVH177, KBVH180) at 0–10 IU/ml quantify viral protein content in vaccine lots and research preparations.
Hepatitis B — Antigen & Antibody Serology Panel
With over 296 million chronic HBV carriers globally and the highest burden in South and Southeast Asia, hepatitis B ELISA remain one of the most frequently requested serology tools in the region. Anti-HBs titre ≥10 mIU/ml is the universally accepted correlate of vaccine-induced protection — making quantitative HBsAb ELISA the primary vaccine immunogenicity endpoint for both primary and booster studies. HBsAg ELISA identify active infection; HBeAg positivity indicates high viral replication and infectivity; anti-HBc IgM distinguishes acute from chronic infection. All markers together constitute the standard hepatitis B serology panel used in clinical trial cohorts and programme evaluation.
Japanese Encephalitis (JEV) & Yellow Fever Virus (YFV)
JEV is endemic across 24 Asian countries and causes approximately 68,000 cases of viral encephalitis annually, with a 30% case fatality rate and 50% long-term neurological sequelae in survivors. Multiple inactivated and live-attenuated vaccines are WHO-prequalified; immunogenicity ELISA measuring JEV IgG seroconversion and long-term antibody persistence are standard endpoints in vaccine programme evaluation across high-burden countries. Yellow Fever is endemic in 47 countries in Africa and the Americas — live-attenuated 17D vaccine confers lifelong immunity in most recipients. YFV IgG ELISA (KBVH605, 30 ng/ml) and IgM ELISA (KBVH606, 30 ng/ml) support post-vaccination surveillance and outbreak serosurveys. Both JEV and YFV assays are validated per WHO TRS guidance for relevant arboviral vaccines and ICH Q2(R2)/Q14.
dsRNA ELISA — Viral Replication Marker, Innate Immune Sensing & mRNA Vaccine QC
Double-stranded RNA (dsRNA) is an obligate intermediate in the replication cycle of all RNA viruses — including every tropical pathogen on this page: Dengue, Zika, Chikungunya, Yellow Fever, JEV, Influenza, RSV, and SARS-CoV-2. As a non-self molecular pattern, dsRNA is recognised by innate immune sensors — TLR3 (endosomal), MDA5 and RIG-I (cytosolic) — triggering type I interferon (IFN-α/β) production and downstream antiviral gene expression. The KRIBIOLISA™ dsRNA J2 ELISA (KBBA56) uses the well-validated J2 anti-dsRNA monoclonal antibody to quantify dsRNA in infected cells, lysates, and tissue samples. It is a standard tool in antiviral drug discovery screening (measuring reduction in dsRNA as a proxy for viral replication inhibition) and in innate immunity research characterising viral evasion of dsRNA sensing. A second critical application is mRNA vaccine manufacturing QC — dsRNA is an immunostimulatory contaminant generated during in vitro transcription (IVT) of mRNA, known to trigger innate responses that reduce mRNA translation efficiency and can contribute to adverse reactogenicity. Accurate dsRNA quantification is therefore essential in the mRNA vaccine production workflow.
KRIBIOLISA™ & GENLISA™ Assay Listing
Click any category to expand the full assay listing. All kits: 1 × 96-well break-apart, ISO 13485-manufactured. For current pricing (USD/INR/GBP) or availability (standard 3–4 weeks lead time), contact info@krishgen.com.
```Arboviral ELISA — Dengue • Zika • Chikungunya • Yellow Fever • JEV
All arboviral ELISA are validated in human serum and plasma as primary matrices. NS1 antigen and envelope protein assays are additionally validated in cell culture supernatant. WHO TRS guidance for relevant arboviral vaccines is referenced in validation documentation. Contact technical@krishgen.com for cross-reactivity data between co-endemic flaviviruses (Dengue, Zika, JEV, YFV).
| Cat No | Assay Name | Target / Format | Sensitivity / Range |
|---|---|---|---|
| Dengue Virus (DENV 1–4) | |||
| DENV-IgG | Dengue IgG Antibody ELISA | IgG Serology • DENV 1–4 | Quantitative |
| DENV-IgM | Dengue IgM Antibody ELISA | IgM Acute Infection | Qualitative |
| DENV-NS1 | Dengue NS1 Antigen ELISA | NS1 Antigen • Early Viraemic Phase | Qualitative / Quantitative |
| Zika Virus (ZIKV — Strain SPH2015) | |||
| KBVH650 | Zika Virus NS1 ELISA | NS1 Antigen • Strain SPH2015 | 50 pg/ml |
| KBVH700 | Zika Virus Envelope Protein (ZIKV-E) ELISA | E Protein • Vaccine Antigen Characterisation | 180 pg/ml |
| ZIKV-IgG | Zika IgG Antibody ELISA | IgG Serology • Seroprevalence | Qualitative |
| ZIKV-IgM | Zika IgM Antibody ELISA | IgM Acute Infection | Qualitative |
| Chikungunya Virus (CHIKV) | |||
| CHIKV-IgG | Chikungunya IgG Antibody ELISA | IgG • Convalescent / Vaccine Immunity | Qualitative |
| CHIKV-IgM | Chikungunya IgM Antibody ELISA | IgM • Acute Alphavirus Infection | Qualitative |
| Yellow Fever Virus (YFV) | |||
| KBVH605 | Yellow Fever Virus IgG ELISA | IgG • Vaccine Immunogenicity | 30 ng/ml |
| KBVH606 | Yellow Fever Virus IgM ELISA | IgM • Acute Infection Marker | 30 ng/ml |
| Japanese Encephalitis Virus (JEV) | |||
| JEV-IgG | Japanese Encephalitis IgG ELISA | IgG Serology • Vaccine Immunogenicity | Qualitative |
| JEV-IgM | Japanese Encephalitis IgM ELISA | IgM • Acute Encephalitis Confirmation | Qualitative |
Rabies Virus — 5-Assay Panel (Glycoprotein & Nucleoprotein)
Krishgen's five-assay rabies panel is one of the most comprehensive ELISA offerings available for rabies vaccine research. Antigen assays quantify glycoprotein and nucleoprotein viral protein content (0–10 IU/ml using WHO reference calibrators). Antibody assays measure post-vaccination IgG across subtypes 1, 2, and 3 in the 6.25–200 U/ml range — spanning both protein targets.
| Cat No | Assay Name | Target | Range |
|---|---|---|---|
| Rabies Antigen Assays | |||
| KBVH177 | Rabies Glycoprotein Antigen ELISA | G Protein Antigen • Vaccine Antigen Quantification | 0–10 IU/ml |
| KBVH180 | Rabies Nucleoprotein Antigen ELISA | N Protein Antigen • Cross-Reactive Antigen | 0–10 IU/ml |
| Rabies IgG Antibody Assays | |||
| KBVH077 | Rabies IgG Antibody ELISA — Subtypes 1, 2, 3 | Pan-subtype IgG • PEP / PrEP Serology | 6.25–200 U/ml |
| KBVH277 | Rabies IgG Antibody to Nucleoprotein ELISA | N Protein-Specific IgG • Cross-Clade Research | 6.25–200 U/ml |
| KBVH377 | Rabies IgG Antibody to Glycoprotein ELISA | G Protein-Specific IgG • Correlates with RFFIT | 6.25–200 U/ml |
Hepatitis B & C • Influenza • RSV • VZV • HIV — Respiratory & Systemic Viral ELISA
Core serological and antigen ELISA for the most researched non-tropical infectious disease targets. All kits ISO 13485-manufactured with Gold Ring QC. For VZV IgG (KBVH601), full ICH Q5A/Q5D referenced documentation is available on request.
| Cat No | Assay Name | Target | Format |
|---|---|---|---|
| Hepatitis B Virus (HBV) | |||
| HBsAg-ELISA | HBsAg (Surface Antigen) ELISA | Active HBV Infection Marker | Qualitative |
| Anti-HBs-ELISA | Anti-HBs (HBsAb) ELISA | Vaccine-Induced Protective Antibody | Quantitative |
| HBeAg-ELISA | HBeAg ELISA | Viral Replication Marker | Qualitative |
| Anti-HBc-ELISA | Anti-HBc IgM / IgG ELISA | Acute vs Past / Chronic Infection Differentiator | Qualitative |
| Hepatitis C Virus (HCV) | |||
| HCV-Ab-ELISA | Anti-HCV IgG Antibody ELISA | HCV Exposure / Seroprevalence | Qualitative |
| HCV-Ag-ELISA | HCV Antigen ELISA | Viral Protein Detection | Qualitative |
| Influenza A & B | |||
| INFA-Ab | Influenza A Antibody ELISA (H1N1, H3N2) | Influenza A IgG • Post-Vaccination Serology | Qualitative |
| INFB-Ab | Influenza B Antibody ELISA | Influenza B IgG • Seasonal Vaccine Monitoring | Qualitative |
| RSV • VZV | |||
| RSV-Ag | RSV Antigen ELISA | RSV Antigen Detection • Prefusion F Research | Qualitative |
| KBVH601 | Varicella-Zoster Virus IgG ELISA (VZV-IgG) | VZV IgG • Varicella / Shingles Vaccine Immunogenicity | 8 ng/ml |
| KBVH602 | Varicella-Zoster Virus IgM ELISA (VZV-IgM) | VZV IgM • Primary Infection / Acute Seroconversion | Qualitative |
Vaccine Manufacturing QC — CRM197 Carrier Protein Quantification
CRM197 (Cross-Reacting Material 197) is the most widely used carrier protein in licensed glycoconjugate vaccines — including those against Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae type b, and Salmonella typhi Vi. Quantifying CRM197 content during conjugation, purification, and final product release ensures batch consistency and supports in-process control. KBVH500 is validated against Fina Biosolutions EcoCRM™ (the reference material used by leading vaccine manufacturers) and has been tested for compatibility with polysaccharide-conjugated matrices. For samples containing high antigen load, polysaccharide-conjugates, or adjuvant, spike-recovery and dilution linearity evaluation is recommended before study use.
| Cat No | Assay Name | Application | Range / LOD |
|---|---|---|---|
| KBVH500 | KRIBIOLISA™ CRM197 Carrier Protein Quantification ELISA | In-process QC • Final product release • Conjugation monitoring • Comparability studies | 5 µg/ml LOD |
dsRNA ELISA — Viral Replication, Innate Immune Sensing & mRNA Vaccine QC
The KRIBIOLISA™ dsRNA J2 ELISA (KBBA56) uses the well-validated J2 monoclonal antibody to detect and quantify double-stranded RNA ≥40 bp in cell lysates, tissue homogenates, and purified RNA preparations. dsRNA is produced as an obligate replication intermediate by all RNA viruses — making it a universal viral replication biomarker applicable across every tropical pathogen in this catalogue. The J2 antibody is the gold-standard reagent for dsRNA detection in innate immunity research and is increasingly used in mRNA vaccine manufacturing QC to measure dsRNA contamination generated during in vitro transcription (IVT), where dsRNA reduces mRNA translation efficiency and contributes to innate reactogenicity.
| Cat No | Assay Name | Application | Detection |
|---|---|---|---|
| KBBA56 | KRIBIOLISA™ dsRNA J2 ELISA | Viral replication marker • Innate immune sensing research • mRNA vaccine IVT dsRNA contaminant QC • Antiviral drug screening (pharmacodynamic biomarker) | dsRNA ≥40 bp • Cell lysates / Purified RNA |
ISO 13485 Certified. Gold Ring QC. Trusted by Vaccine Manufacturers across Asia, Africa and Latin America.
Krishgen is a dedicated ELISA manufacturer — not a distributor. All kits are produced in ISO 13485 and CDSCO-certified Class 7/8 cleanrooms in Mumbai and California. Every assay is validated against Krishgen's seven-point "Gold Ring" QC protocol: lot-to-lot consistency, dilutional linearity, recovery, intra- and inter-assay precision, stability, and sensitivity. This ensures results are reproducible across both research sites and production batches — critical for multi-site serosurveillance studies and vaccine lot release programmes.
Our rabies panel (5 assays) is one of the most complete commercially available ELISA offerings for the target, covering both viral structural protein antigens and three distinct antibody measurement formats. Our arboviral portfolio — spanning Dengue, Zika, Chikungunya, Yellow Fever, and JEV — is built for the practical realities of research in dual-endemic regions, with cross-reactivity characterisation available on request.
For vaccine manufacturing applications, the KRIBIOLISA™ CRM197 ELISA has been validated against Fina Biosolutions EcoCRM™ and tested for compatibility with polysaccharide-conjugated matrices across multiple conjugate vaccine programmes. The dsRNA J2 ELISA (KBBA56) adds a cross-cutting innate immunity layer — applicable across every RNA virus in this catalogue and to mRNA vaccine manufacturing QC.
Frequently Asked Questions
Custom Services & Specialist Enquiries
Krishgen's in-house manufacturing capability means we can develop novel viral antigen or antibody ELISA to order, validate in non-standard matrices, or provide Genbulk™ packs for high-throughput serosurveillance and vaccine lot release programmes.
Need a Specific Pathogen or Matrix Validation?
Krishgen manufactures infectious disease ELISA across 15+ virus families. Our technical team can identify the right assay, confirm cross-reactivity and matrix validation data, or custom-develop a new kit for your target pathogen or study design.